Sarah is a seasoned oncology strategist with over 20 years of experience in oncology drug development across all indications and phases. She has a proven track record of leading clinical operations, global project management, and portfolio oversight, with a focus on advancing innovative treatments to patients and their care families. Currently serving as the Therapeutic Strategy Lead – Oncology at Novotech, Sarah leverages her extensive expertise to develop and deliver successful oncology strategies. Her career includes leadership roles at prominent organizations such as Worldwide Clinical Trials, Covance (now LabCorp), and Synteract (now Syneos), where she demonstrated a deep understanding of clinical delivery and operational excellence. Sarah is a passionate advocate for improving patient outcomes and brings a strategic, patient-centric approach to every project she undertakes. Her undergraduate studies focused on biological sciences at Notre Dame College of Ohio.
